Markus Joerger


Affiliation: St. Gallen
Country: Switzerland


  1. Hoemme A, Barth H, Haschke M, Krahenbuhl S, Strasser F, Lehner C, et al. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol. 2019;: pubmed publisher
    ..32, p = 0.049) in the adjusted model. In conclusion, PDI are frequent in patients with advanced cancer and increased caution with polypharmacy is warranted when treating such patients. ..
  2. O Brien O, Wright M, O Brien C, Geoghegan O, Leonard N, Nicholson S, et al. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. Diagnostics (Basel). 2019;9: pubmed publisher
    ..In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution in NSCLC. ..
  3. Joerger M, Ess S, Dehler S, Savidan A, Bouchardy C, Frick H, et al. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly. 2012;142:w13571 pubmed publisher
    ..Further epidemiological studies should assess how the use of FAC-T chemotherapy is affecting clinical outcome in patients with early BC and different risk profiles. ..
  4. Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, et al. Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. Invest New Drugs. 2015;33:472-9 pubmed publisher
  5. Joerger M, Ferreri A, Krahenbuhl S, Schellens J, Cerny T, Zucca E, et al. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol. 2012;73:240-7 pubmed publisher
    ..The clinical benefit of this dosing algorithm should be assessed in patients with primary central nervous system lymphoma (PCNSL). ..
  6. request reprint
    Joerger M, Omlin A, Cerny T, Fruh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets. 2010;11:37-47 pubmed
    ..These are important steps towards individualisation of anticancer treatment in patients with advanced NSCLC. ..
  7. Joerger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol. 2015;11:691-702 pubmed publisher
    ..Finally, treating oncologists should be aware of the substantial risk for drug-drug interactions that is a direct consequence of the complex hepatic metabolism of the taxanes. ..
  8. Joerger M, Thurlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther. 2013;13:165-78 pubmed publisher
  9. Joerger M, Thurlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, et al. A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. Clin Breast Cancer. 2012;12:102-9 pubmed publisher
    ..Improvements should be made to increase the weight of tumor biological features in choosing chemotherapy in early BC. ..

More Information


  1. Joerger M, Burgers S, Baas P, Smit E, Haitjema T, Bard M, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118:2466-75 pubmed publisher
    ..Nonplatinum-containing chemotherapy in carriers of the ERCC1 T allele or the XPD10 G allele should be studied prospectively. ..
  2. Crombag M, Joerger M, Thürlimann B, Schellens J, Beijnen J, Huitema A. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel). 2016;8: pubmed publisher
  3. Joerger M, Von Pawel J, Kraff S, Fischer J, Eberhardt W, Gauler T, et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2016;27:1895-902 pubmed publisher
    ..NCT01326767 ( ..
  4. Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, et al. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer. 2016;100:38-44 pubmed publisher
    ..The present study suggests erlotinib to have similar clinical efficacy compared to chemotherapy in patients with pretreated advanced NSCLC and no known molecular targetable alterations. ..
  5. Joerger M. Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol. 2016;77:221-33 pubmed publisher
    ..The latter includes the ongoing debate on the most active and safe regimen, the recommended initial dose and the issue of therapeutic drug dosing. ..
  6. Joerger M, Thurlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol. 2011;22:17-23 pubmed publisher
    ..This review addresses current data regarding the prognosis of small HER2-positive tumors and discusses potential factors to individualize adjuvant treatment in patients with small HER2-positive tumors. ..
  7. Joerger M, Huitema A, Boot H, Cats A, Doodeman V, Smits P, et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol. 2015;75:763-72 pubmed publisher
    ..These data should further be validated in prospective clinical studies. ..
  8. Joerger M, DeJong D, Burylo A, Burgers J, Baas P, Huitema A, et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer. 2011;74:310-7 pubmed publisher
    ..Prospective validation is warranted and - if confirmed - non platinum-containing chemotherapy should be explored as the preferred treatment in patients with high ERCC1 or ABRX expression and no activating mutations of EGFR. ..
  9. Gachechiladze M, Skarda J, Kolek V, Grygarkova I, Langova K, Bouchal J, et al. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer. 2017;105:31-38 pubmed publisher
  10. Joerger M, Huitema A, Krahenbuhl S, Schellens J, Cerny T, Reni M, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102:673-7 pubmed publisher
    ..In the future, this could be carried out by using first-cycle PK modelling with determination of potential dose adaptations for later cycles using Bayesian analysis. ..